Detalhe da pesquisa
1.
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
N Engl J Med
; 387(1): 9-20, 2022 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35665782
2.
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.
Lancet Oncol
; 25(5): 614-625, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38697155
3.
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.
Lancet
; 401(10390): 1773-1785, 2023 05 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37086745
4.
The impact of germline BRCA pathogenic variants in locally advanced, triple negative breast cancer treated with platinum-based neoadjuvant chemotherapy.
Breast Cancer Res Treat
; 2024 Feb 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38345692
5.
BRCA1/2 mutation carriers vs the general breast cancer population (N = 799,986): 21-gene assay-based molecular characterization.
Breast Cancer Res Treat
; 2024 Apr 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38568368
6.
Central nervous system metastases in breast cancer patients with germline BRCA pathogenic variants compared to non-carriers: a matched-pair analysis.
BMC Cancer
; 24(1): 219, 2024 Feb 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38365640
7.
Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel.
J Med Genet
; 60(12): 1186-1197, 2023 Nov 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37451831
8.
Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study.
JAMA
; 331(1): 49-59, 2024 01 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38059899
9.
Rate of breast biopsy referrals in female BRCA mutation carriers aged 50 years or more: a retrospective comparative study and matched analysis.
Breast Cancer Res Treat
; 193(2): 507-514, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35391652
10.
[RAPIDLY PROGRESSING PARAPARESIS AND LOSS OF SENSATION BELOW T10 DURING NEOADJUVANT CHEMOTHERAPY FOR BREAST CANCER].
Harefuah
; 161(1): 14-16, 2022 Jan.
Artigo
em Hebraico
| MEDLINE | ID: mdl-35077053
11.
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
N Engl J Med
; 379(8): 753-763, 2018 08 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-30110579
12.
Taxane versus vinorelbine in combination with trastuzumab and pertuzumab for first-line treatment of metastatic HER2-positive breast cancer: a retrospective two-center study.
Breast Cancer Res Treat
; 188(2): 379-387, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33772709
13.
Central nervous system metastases in breast cancer: the impact of age on patterns of development and outcome.
Breast Cancer Res Treat
; 185(2): 423-432, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33037977
14.
Genetic testing in patients with triple-negative or hereditary breast cancer.
Curr Opin Oncol
; 33(6): 584-590, 2021 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34474437
15.
The Impact of Exogenous Estrogen Exposure on the Characteristics and Outcome of Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer.
Oncology
; 99(11): 713-721, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34515186
16.
3,3-Diindolylmethane (DIM): a nutritional intervention and its impact on breast density in healthy BRCA carriers. A prospective clinical trial.
Carcinogenesis
; 41(10): 1395-1401, 2020 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32458980
17.
Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer.
Breast Cancer Res Treat
; 182(2): 259-266, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32488391
18.
Diagnostic workup of early-stage breast cancer: can we choose more wisely?
Breast Cancer Res Treat
; 183(3): 741-748, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32728861
19.
GRP78 expression in peripheral blood mononuclear cells is a new predictive marker for the benefit of taxanes in breast cancer neoadjuvant treatment.
BMC Cancer
; 20(1): 333, 2020 Apr 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-32306920
20.
Intraoperative radiation therapy for breast cancer-Immediate and 30-month oncological outcomes.
Breast J
; 26(5): 946-951, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31876341